Cardiovascular effects of chronic nitric oxide synthase inhibition in genetically hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 7, 2000, Pages 488-493

  Orange, Stefan J ^a,b   Ledingham, Janet M ^a   Laverty, Richard ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Blood pressure; Genetically hypertensive rat; N( ) nitro L arginine methyl ester; Nitric oxide; Nitric oxide synthase inhibition; Rat hindquarter

Indexed keywords

ACETYLCHOLINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HEART LEFT VENTRICLE HYPERTROPHY; HEREDITARY HYPERTENSION; HYPERTENSION; NONHUMAN; PERFUSION PRESSURE; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

AGING; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEART RATE; HEMODYNAMIC PROCESSES; HINDLIMB; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW;

EID: 0034086501     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03279.x     Document Type: Article

References (36)

1. 1. Quyyumi AA, Dakak N, Andrews NP et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J. Clin. Invest. 1995; 95: 1747-55.
2. 2. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994; 89: 2035-44.
3. G-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br. J. Pharmacol. 1990; 101: 625-31.
4. 4. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
5. 5. Taddei S, Virdis A, Ghiadoni L, Salvatti A. Hypertension and endothelial dysfunction. Cardiovasc. Risk Factors 1997; 7: 76-87.
6. 6. Drexler H. Endothelial dysfunction: Clinical implications. Prog. Cardiovasc. Dis. 1997; 39: 287-324.
7. 7. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
8. 8. Moore PK, Handy RL. Selective inhibitors of neuronal nitric oxide synthase: Is no NOS really good NOS for the nervous system? Trends Pharmacol. Sci. 1997; 18: 204-11.
9. 9. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 1990; 101: 746-52.
10. ω-nitro-L-arginine methyl ester on vasodilator responses to acetylcholine, bradykinin, and substance P. Eur. J. Pharmacol. 1994; 254: 207-12.
11. 11. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension 1999; 33: 937-42.
12. 12. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 1995; 25: 1202-11.
13. 13. Winquist RJ, Bunting PB, Baskin EP, Wallace AA. Decreased endothelium-dependent relaxation in New Zealand genetic hypertension rats. J. Hypertens. 1984; 2: 541-5.
14. ω-nitro-L-arginine methyl ester affects blood pressure and cardiovascular structure in the genetically hypertensive rat strain. Clin. Exp. Pharmacol. Physiol. 1997; 24: 433-5.
15. 15. Phelan EL. The New Zealand strain of rats with genetic hypertension. N.Z. Med. J. 1968; 67: 334-44.
16. 16. Simpson FO, Phelan EL, Ledingham JM, Millar JA. Hypertension in the genetically hypertensive (GH) strain. In: Ganten D, de Jong W (eds). Handbook of Hypertension, Vol. 16. Experimental and Genetic Models of Hypertension. Elsevier Science BV, Amsterdam. 1994; 228-71.
17. 17. Smirk FH, Fastier FN. Circulatory properties of iso-thioureas, guanidines, iso-ureas and amidines. J. Pharmacol. Exp. Ther. 1947; 89: 256-70.
18. 18. Mulvany MJ, Hansen OK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ. Res. 1978; 43: 854-64.
19. 19. Minami N, Imai Y, Hashimoto J, Abe K. Contribution of vascular nitric oxide to basal blood pressure in conscious spontaneously hypertensive rats and normotensive Wistar Kyoto rats. Clin. Sci. 1995; 89: 177-82.
20. 20. Akiba Y, Yamaguchi N, Amano H et al. Role of nitric oxide in the control of blood pressure in young and adult spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1995; 22 (Suppl. 1): S142-3.
21. 21. Gil-Longo J, Fernandez-Grandal D, Alvarez M, Sieira M, Orallo F. Study of in vivo and in vitro resting vasodilator nitric oxide tone in normotensive and genetically hypertensive rats. Eur. J. Pharmacol. 1996; 310: 175-83.
22. 22. Rees D, Ben-Ishay D, Moncada S. Nitric oxide and the regulation of blood pressure in the hypertension-prone and hypertensive-resistant Sabra rat. Hypertension 1996; 28: 367-71.
23. 23. Deng AY. Is the nitric oxide system involved in genetic hypertension in Dahl rats? Kidney Int. 1998; 53: 1501-11.
24. 24. Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension 1993; 22: 380-7.
25. ω-nitro-L-arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate-salt hypertensive rats. J. Hypertens. 1996; 14: 1331-9.
26. 26. Angus JA, Dyke AC, Jennings GL et al. Release of endothelium-derived relaxing factor from resistance arteries in hypertension. Kidney Int. 1992; 41 (Suppl. 37): S73-8.
27. 27. Dowell FJ, Henrion D, Duriez M, Michel JB. Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats. Br. J. Pharmacol. 1996; 117: 341-6.
28. G-nitro-L-arginine in anaesthetized rats. Clin. Exp. Pharmacol. Physiol. 1998; 25: 510-16.
29. G-nitro-L-arginine methyl ester in rats and cats. Br. J. Pharmacol. 1991; 103: 1899-904.
30. 30. Brouwers-Ceiler DL, Nelissen-Vrancken HJ, Smits JF. Effect of nitric oxide synthase inhibition on the acetylcholine response in the perfused hind limb of rats. Eur. J. Pharmacol. 1996; 307: 65-8.
31. 31. Davisson RL, Bates JN, Johnson AK, Lewis SJ. Use-dependent loss of acetylcholine-and bradykinin-mediated vasodilation after nitric oxide synthase inhibition. Evidence for preformed stores of nitric oxide-containing factors in vascular endothelial cells. Hypertension 1996; 28: 354-60.
32. 32. Moncada S, Rees DD, Schulz R, Palmer RM. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl Acad. Sci. USA 1991; 88: 2166-70.
33. 33. Phelan EL, Eryetishir I, Smirk FH. Observation of the responses of rats with spontaneous hypertension and control rats to pressor drugs and to hexamethonium. Circ. Res. 1962; 10: 817-24.
34. 34. Phelan EL. Cardiovascular reactivity in rats with spontaneous inherited hypertension and constricted renal artery hypertension. Am. Heart J. 1966; 71: 50-7.
35. 35. Laverty R. Increased vascular reactivity in rats with genetic hypertension. Proc. Univ. Otago Med. School 1961; 19: 23-4.
36. 36. Phelan EL, Simpson FO. Vascular reactivity in genetically hypertensive and spontaneously hypertensive rats. J. Hypertens. 1986; 4 (Suppl. 3): S57-9.